SGLT2i and GLP1-RAs: The Sweet Move
Presenter
Schuyler Schuyler Jones, M.D., Duke University Medical Center, Chapel Hill, NC
Schuyler Schuyler Jones, M.D., Duke University Medical Center, Chapel Hill, NC
Learning Objectives:
- Describe the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists.
- Select appropriate patients for cardiometabolic therapy based on comorbidities.
- Integrate these agents into broader cardiovascular risk reduction strategies.